Summary The prodrug N[4-(daunorubidn-N-carbony -oxymethyl)phenyl] 04i-glucuronyl carbamate (DNR-GA3) was synthesized for specific acfivation by human fi-glucuronidase, released in necrotic areas of tumour lesions. In vitro, DNR-GA3 was 18 times less toxic than daunorubicin (DNR) and the prodrug was completely activated to the parent drug by human 0-glucuronidase. The maximum tolerated dose of DNR-GA3 in nude mice bearing s.c. human ovarian cancer xenografts was 6-10 times higher than that of DNR. The prodrug was cleared more rapidly from the circulation (elimination t,2 = 20 min) than the parent drug (elimination t12= 720 min). The anti-tumour effects of DNR-GA3 and DNR were investigated in four different human ovarian cancer xenografts OVCAR-3, FMa, A2780 and MRI-H-207 at a mean tumour size between 100 and 200 mm3. In three out of four of these tumour lines, the prodrug given i.v. at the maximum tolerated dose ranging from 150 to 250 mg kg-' resulted in a maximum tumour growth inhibition from 82% to 95%. The standard treatrnent with DNR at a dose of 8 mg kg-' given i.v. weekly x 2 resulted only in a maximum tumour growth inhibition from 400/o to 47%. Tumour line FMa did not respond to DNR, nor to DNR-GA3. Treatment with DNR-GA3 was also given to mice with larger tumours that would contain more necrosis (mean size 300-950 mm3). The specific growth delay by DNR-GA3 was extended from 2.1 to 4.4 in OVCAR-3 xenografts and from 4.4 to 6.0 in MRI-H-207 xenografts. Our data indicate that DNR-GA3 is more effective than DNR and may be especially of use for treatnent of tumours with areas of necrosis.
University Hospital Vnje Universiteit, PO Box 7057, 1007 MB Amsterdam, The Netherlands Campeneere et al. 1982) . In human ovarian cancer xenografts. N-L-leucyl-DOX was shown to be more effective than DOX (Boven et al. 1992) . Clinical studies on N-L-leucyl-DOX have yet to be completed.
Human >-glucuronidase is another enzyme in which levels are elevated in tumour tissue when compared with normal tissues (Connors and Whisson, 1966) . Albin et al (1993) have shown that the concentration of S-glucuronidase was six times higher in breast cancer tissue of patients than in peritumoral tissue. when measuring the enzyme activity of tissue homogenates. Bosslet et al (1995) and Schumacher et al (1996) have shown by enzyme histochemistry that S-glucuronidase was expressed in a wide range of tumour types and was particularly localized in necrotic areas. The enzyme can only be detected in very low concentrations in the circulation (Fishman. 1970) . It is hypothesized that anthracycline-glucuronide prodrugs may be selectively activated in tumour tissue on the basis of high fr.glucuronidase levels released by necrotic cells. We have developed such a glucuronide prodrug of DNR: N-[4-(daunorubicin-N-carbonyl-oxymethyl) phenyll O->-glucuronyl carbamate (DNR-GA3) (R. G. G. Leenders. submitted: Figure 1) .
In the present studies. we compared the antiproliferative effects of DNR-GA3 and DNR in vitro and their respective elimination half-life times (t,,: ) from the circulation of mice. After determination of the maximum tolerated dose (MTD) of DNR-GA3 in tumour-bearing mice. the efficacy of the prodrug was compared with that of DNR in four human ovarian cancer xenografts. Large tumours have more necrosis than small tumours and were expected to contain more extracellular S-glucuronidase. Therefore. special attention was paid to the influence of the tumour size on drug effects.
MATERIALS AND METHODS Cell lines and reagents
The human oxarian cancer cell line N-IH:OV-CAR-3 (Hamilton et al. 1983) Differences in efficacy between treatment groups were expressed as the percentage of maximum growth inhibition (GI). The relative tumour volume was expressed by the formula VT/VO where VT is the volume on any given day and V0 is the volume on day 0. The ratio between the mean of the relative volumes of treated tumours and that of control tumours x 100% (T/C%) was assessed on each day of measurement and used to calculate the GI (GI = 100% -T/C%). The maximum GI was scaled as follows: GI .50% was defined as not sensitive. 50% < GI < 75% was defined as sensitive, and GI >75% was defined as very sensitive (Boven et al. 1988 Figure   2 ). This indicates that the relatively non-toxic prodrug was completely activated to the toxic drug by the enzyme. Decomposition of the carbamate spacer will liberate 4-aminobenzyl alcohol. When OVCAR-3 cells were incubated with 4-aminobenzyl alcohol alone. no toxicity was observed at concentrations up to 100 gm (data not shown).
Kinetics of DNR-GA3 and DNR
The pharmacokinetics of the prodrug and the drug were determined in BALB/c mice (Figure 3) . DNR cleared slowly from the blood with a terminal tV,: of 720 min (n-=3) and was detectable for more than 24 h in the circulation. DNR-GA3 cleared rapidly with a terminal t1,2 of 20 min (n=3). At 4 h. the DNR-GA3 concentration was under the detection limit of 0.01 Jm. After the i.v. administration of DNR-GA3, no DNR was detectable in the plasma of the mice.
Maximum tolerated dose (MTD) and toxicity For DNR. a dose of 10 mg kg-1 i.v. weekly x 2 studied in OVCAR-3-bearing mice was too toxic because five out of six mice suffered from ascites and rapid death between 16 and 92 days after the first injection. DNR 8 mg kg-' i.v. weekly x 2 was well tolerated in subsequent treatment experiments. (1998) 78(12), 1600-1606 Days after initial treatment Anthracycline prodrug therapy 1605 than DNR (P<0.01). Also. the higher dose of 2 x 200mg kg-' DNR-GA3 was slightly. but not significantly. more effective than the lower dose of 2 x 150 mg kg-' DNR-GA3 ( Figure 5 ). Similar data were obtained for the MRI-H-207 tumour line in which 200 mg kg-' DNR-GA3 on day 0 was more effective than the lower dose of 100 mg kg-' DNR-GA3 on day 0 (P < 0.002) ( Figure 4 and Table 2 ).
DISCUSSION
The objective of this study was to investigate the potential increase in the therapeutic index of the glucuronide prodrug DNR-GA3 when compared with DNR. In vitro. the prodrug was 18-fold less toxic than DNR. In mice bearing human ovarian cancer xenografts. the MTD of DNR-GA3 was six-to tenfold higher than that of DNR. The prodrug was apparently activated in the tumours by f-glucuronidase and inhibited tumour growth in human ovarian cancer xenografts that were sensitive to the parent drug DNR. In these three xenografts (OVCAR-3. A2780. and MRI-H-207) . the inhibitory effect at MTD was better than the tumour growth delay obtained with the parent drug. The different DNR-glucuronide prodrugs synthesized were designed to be rapidly activated in the presence of human >-glucuronidase. DNR-GA3 was most rapidly activated in vitro by human o-glucuronidase (Houba et al. 1996a) . and was chosen for in vivo analysis. DNR-GA3 is stable in vivo. it is a hydrophilic molecule that hardly passes through the cell membrane into the cell. DNR-GA3 will. therefore. not be activated by intracellular fglucuronidase. Activation in the circulation is also less likely as the plasma levels of P-glucuronidase are very low (Fishman. 1970) . Bosslet et al (1995) and Schumacher et al (1996) have demonstrated high levels of f-glucuronidase in necrotic areas in tumours. Therefore. it could be expected that DNR-GA3 will be activated selectively by human S-glucuronidase released from necrotic tumour cells.
The difference in MTD between DNR-GA3 and DNR in mice bearing human ovarian cancer xenografts may be explained by the more rapid clearance of DNR-GA3 (elimination t,:, = 20 min) than that of DNR (elimination ty. = 720 min) from the circulation. Thus far. we have no information on the nature of the dose-limiting toxicity in mice. We observed. however. the formation of ascites at higher doses of DNR-GA3 as also described for DNR (Boven et al. 1996) . The variation in the MTD of DNR-GA3 found among the four different human ovarian cancer xenografts may possibly be clarified by differences in activation and leakage of DNR from the tumours into the circulation.
The treatment expenrments showed that the prodrug DNR-GA3 induced better inhibition of growth in three out of four human ovarian cancer xenografts than equitoxic doses of DNR (OVCAR-3. A2780 and MRI-H-207). This observation may be explained by higher local DNR concentrations in the tumour from activated DNR-GA3. Earlier. it has been demonstrated that there is a steep dose-response curve for anthracyclines (Frei and Canellos. 1980) . Bosslet et al (1995) have described that s.c. grown LoVo colon cancer xenografts with a diameter larger than 2 mm had necrotic areas. where S-glucuronidase was present in high concentrations. This group has also demonstrated that a glucuronyl-spacer-DOX prodrug showed better therapeutic effects than DOX.
It was hypothesized that large tumours contain more necrosis and. thus. more $-glucuronidase would be available to activate DNR-GA3. Indeed, we calculated a relatively longer increase in two volume-doubling times for large tumours of the OVCAR-3 and the MRI-H-207 tumour lines when compared with the values of the respective small tumours. With respect to the clinic. this finding is of interest because the treatment of patients with large tumour deposits remains a challenge.
The administration of anthracycline prodrugs to be activated at the tumour site may induce an even better growth inhibition when combined with a second approach: antibody-directed enzyme prodrug therapy (ADEPT: Bagshawe et al. 1988 ). In ADEPT. prodrugs are activated in the tumour by an administered tumourspecific monoclonal antibody-enzyme conjugate. In our point of view. DNR-GA3 is very suitable for ADEPT. We have shown earlier that a conjugate of monoclonal antibody 323/A3 and human f-glucuronidase bound to tumour cells can activate DNR-GA3 in an efficient manner (Haisma et al. 1992 : Houba et al. 1996b ). If such a tumour-specific conjugate is administered before DNR-GA3 injection. activation could also occur in the nonnecrotic smaller tumour lesions.
In conclusion. our findings suggest that the glucuronidated anthracycline DNR-GA3 may have a better therapeutic index in advanced solid tumours in which anthracychnes are considered for treatment.
